Physician profile

Mathew Cholankeril

Cardiovascular Disease · Rahway, NJ

NPI 1588694780

$16,936.83

in general payments reported to CMS, 2019-2025

37 companies · $945 in 2025

The $945 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$3,706.95

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Ge Healthcare $6,775.98 2020
Abbott Laboratories $2,782.72 2019-2025 Aveir, Jot Dx, Gallant
Astrazeneca Pharmaceuticals LP $2,233.09 2019-2025 Farxiga, Breztri
Baxter Healthcare $708.77 2022-2025 Hillrom - Carnation Ambulatory Monitor
Novartis Pharmaceuticals Corporation $579.00 2019-2025
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $430.76 2019-2024 Lifevest
Biotronik INC. $411.25 2019-2020
Merck Sharp & Dohme LLC $323.39 2019-2024 Verquvo
Novo Nordisk INC $277.40 2019-2025 Ozempic, Rybelsus
Shockwave Medical, INC $255.83 2021-2024 Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary
Boston Scientific Corporation $216.56 2023 Lux-Dx Insertable Cardiac Monitor, Mylux Patient Kit With Mobile Device, Watchman Access System
Medtronic, INC. $201.82 2022-2025 Ffrangio, Onyx Frontier, Symplicity G3
Vifor Pharma, INC. $200.00 2021
Boehringer Ingelheim Pharmaceuticals, INC. $177.70 2020-2024 Jardiance
Bayer Healthcare Pharmaceuticals INC. $171.78 2021-2024
Show all 37 companies
CompanyGeneral paymentsYearsTop products
Janssen Pharmaceuticals, INC $145.14 2019-2024 Xarelto
Abiomed $120.50 2025
Amarin Pharma, INC. $117.01 2019-2021
E.R. Squibb & Sons, L.L.C. $108.13 2019-2025 Camzyos, Eliquis
Kowa Pharmaceuticals America, INC. $102.16 2022
Pfizer INC. $101.21 2019-2023
Scpharmaceuticals INC. $66.94 2024-2025
Lexicon Pharmaceuticals, INC. $55.40 2023 Inpefa
Lilly USA, LLC $40.36 2019-2020
Daiichi Sankyo INC. $39.58 2019-2023 Injectafer
Cordis US Corp. $39.25 2022-2024 Mynxgrip
Acist Medical Systems, INC. $35.41 2025
Penumbra, INC. $34.39 2021-2024 Indigo System
Medtronic Vascular, INC. $33.51 2019
Bardy Diagnostics, INC. $30.00 2020
Amgen INC. $28.62 2020-2021
Atricure, INC. $24.36 2025 Atriclip Laa Exclusion System
Edwards Lifesciences Corporation $17.98 2024 Edwards Sapien 3 Transcatheter Heart Valve (Thv)
Mannkind Corporation $15.00 2019
Otsuka America Pharmaceutical, INC. $12.93 2021
Glaxosmithkline, LLC. $12.90 2021
Althera Pharmaceuticals LLC $10.00 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Mathew Cholankeril

$16,936.83

in general payments reported 2019-2025

Years
2019-2025
Top company
Ge Healthcare
Context
The $945 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/522151/mathew-cholankeril

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.